90results about How to "Induced proliferation" patented technology

It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.

The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.

The invention provides a carbon fiber composite artificial bone and a preparation method thereof. The section of the artificial bone in a direction perpendicular to the length of the artificial bone is in a U shape, continuous carbon fiber woven fabric composite material layers and carbon fiber non-woven fabric composite material layers are stacked to form the artificial bone, and spaces among thecarbon fibers of the continuous carbon fiber woven fabric composite material layers and the carbon fiber non-woven fabric composite material layers are filled with carbon substrates. The carbon fibercomposite artificial bone has the advantages that the composite material is light in weight, good in biocompatibility, chemical stability and fatigue performance and high in designability, the mechanical property of the composite material is similar to that of a human bone, fake shadows are avoided and the like, hydroxylapatite is stably adhered onto gaps in the surface and the surface, so that biological activity of the composite material is improved, bone growth is facilitated, and bone proliferation is induced.

The invention provides antigenic peptides derived from MAGE-A12 polypeptides and presented by HLA molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.

The invention provides a method for preparing antibacterial wound dressing with a high chitosan content by means of electrostatic spinning. The method includes preparing mixed solvents for dissolving chitosan; adding the chitosan and polyethylene oxide with an ultrahigh molecular weight into the mixed solvents and heating and stirring the chitosan, the polyethylene oxide and the mixed solvents to obtain mixed solution; carrying out ultrasonic oscillation on the mixed solution and further heating the mixed solution to obtain spinning solution; preparing the antibacterial wound dressing from the obtained spinning solution by the aid of an electrostatic spinning process. The mixed solvents are prepared from nanometer silver solution, dimethyl sulfoxide, acetic acid and surfactants. The method has the advantages that the method is easy and convenient to implement and good in repeatability, the antibacterial wound dressing prepared by the aid of the method is of a nanometer fiber structure, and proliferation, adhesion, spreading and migration of cells can be induced; excellent antibacterial effects can be realized, the antibacterial wound dressing is excellent in biocompatibility, bionic artificial skins are of structures similar to structures of natural skins, accordingly, infection due to diabetes mellitus can be effectively cured, and the antibacterial wound dressing has huge application potential in diabetes mellitus ulcerative wound treatment.

This invention provides compositions, methods and kits for the diagnosis and treatment of cancers wherein Wnt Inhibitory Factor-1 (WIF-1) is underexpressed.

The present invention discloses cell lines and recombinant growth factor receptors useful in adoptive cell therapy (ACT), wherein the recombinant growth factor receptor can act as a molecular switch enabling cells expressing the rGFR protein to be expanded in-vitro or in- vivo. Thus the invention provides a T or NK cell, comprising a recombinant growth factor receptor (rGFR) comprising: (i) an extracellular (EC) domain; (ii) a thrombopoietin receptor transmembrane (TM) domain; and (iii) a growth factor receptor intracellular (IC) domain.

The invention relates to in-vitro culture of immune cells and in particular relates to in-vitro induction culture of CIK cells. The preparation method disclosed by the invention comprises the following steps: coating a cell culture bottle by fibronectin and a CD3 monoclonal antibody; preparing autologous plasma; acquiring peripheral blood mononuclear cells PBMC; inducing the PBMC by IL-2, IFN-gamma and the autologous plasma; and performing multiplication culture. The CIK cells prepared by the preparation method disclosed by the invention are great in quantity of CIK cells, high in cell viability, high in ratio of CD3+CD56+effector cells and high in cytolytic activity, can meet clinical requirements and have high anti-tumor abilities.

The invention provides a cellular immunotherapy therapy product comprising CAR T cells that are enriched in CD8+ cells. Also provided are methods for making and using the product.